Abstract Details

Title PEGylated Interferon Beta-1a Pharmacokinetics, Pharmacodynamics, and Safety in Subjects with Normal or Impaired Renal Function

Topic MS and Related Diseases

Presentation(s) (-)

Poster/Presentation
Number 165

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Xiao Hu, PhD (Biogen Idec)	No disclosure on file
Ali Seddighzadeh	No disclosure on file
	No disclosure on file
Larisa Miller, PharmD	Larisa Miller, PharmD has received personal compensation for serving as an employee of Alexion Pharmaceuticals, Inc. Larisa Miller, PharmD has received stock or an ownership interest from Alexion Pharmaceutical, Inc.
Ying Zhu	No disclosure on file
Francois Curtin	No disclosure on file
Serena W. Hung, MD	Dr. Hung has received personal compensation for serving as an employee of Atalanta Therapeutics. Dr. Hung has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for LoQus23 . Dr. Hung has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AS2 Bio. Dr. Hung has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for National Ataxia Foundation. Dr. Hung has or had stock in Atalanta Therapeutics.

�鶹��ýӳ��